Literature DB >> 18292811

Complex two-gene modulation of lung disease severity in children with cystic fibrosis.

Ruslan Dorfman1, Andrew Sandford, Chelsea Taylor, Baisong Huang, Daisy Frangolias, Yongqian Wang, Richard Sang, Lilian Pereira, Lei Sun, Yves Berthiaume, Lap-Chee Tsui, Peter D Paré, Peter Durie, Mary Corey, Julian Zielenski.   

Abstract

Although cystic fibrosis (CF) is a monogenic disease, its clinical manifestations are influenced in a complex manner. Severity of lung disease, the main cause of mortality among CF patients, is likely modulated by several genes. The mannose-binding lectin 2 (MBL2) gene encodes an innate immune response protein and has been implicated as a pulmonary modifier in CF. However, reports have been conflicting, and interactions with other modifiers have not been investigated. We therefore evaluated the association of MBL2 with CF pulmonary phenotype in a cohort of 1,019 Canadian pediatric CF patients. MBL2 genotypes were combined into low-, intermediate-, and high-expression groups based on MBL2 levels in plasma. Analysis of age at first infection with Pseudomonas aeruginosa demonstrated that MBL2 deficiency was significantly associated with earlier onset of infection. This MBL2 effect was amplified in patients with high-producing genotypes of transforming growth factor beta 1 (TGFB1). Similarly, MBL2 deficiency was associated with more rapid decline of pulmonary function, most significantly in those carrying the high-producing TGFB1 genotype. These findings provide evidence of gene-gene interaction in the pathogenesis of CF lung disease, whereby high TGF-beta1 production enhances the modulatory effect of MBL2 on the age of first bacterial infection and the rate of decline of pulmonary function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292811      PMCID: PMC2248329          DOI: 10.1172/JCI33754

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  60 in total

Review 1.  The lectin-complement pathway--its role in innate immunity and evolution.

Authors:  Teizo Fujita; Misao Matsushita; Yuichi Endo
Journal:  Immunol Rev       Date:  2004-04       Impact factor: 12.988

2.  Polymorphisms in the mannose binding lectin gene affect the cystic fibrosis pulmonary phenotype.

Authors:  J Yarden; D Radojkovic; K De Boeck; M Macek; D Zemkova; V Vavrova; R Vlietinck; J-J Cassiman; H Cuppens
Journal:  J Med Genet       Date:  2004-08       Impact factor: 6.318

3.  Five- to seven-year course of pulmonary function in cystic fibrosis.

Authors:  M Corey; H Levison; D Crozier
Journal:  Am Rev Respir Dis       Date:  1976-12

Review 4.  Mannan-binding lectin and its role in innate immunity.

Authors:  D C Kilpatrick
Journal:  Transfus Med       Date:  2002-12       Impact factor: 2.019

5.  Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Authors:  R J Knudson; M D Lebowitz; C J Holberg; B Burrows
Journal:  Am Rev Respir Dis       Date:  1983-06

6.  Transforming growth factor-beta inhibits lipopolysaccharide-stimulated expression of inflammatory cytokines in mouse macrophages through downregulation of activation protein 1 and CD14 receptor expression.

Authors:  K Imai; A Takeshita; S Hanazawa
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Relationship between gene polymorphisms of mannose-binding lectin (MBL) and two molecular forms of MBL.

Authors:  Itaru Terai; Kunihiko Kobayashi; Masanao Matsushita; Hiroshi Miyakawa; Naoki Mafune; Hideaki Kikuta
Journal:  Eur J Immunol       Date:  2003-10       Impact factor: 5.532

Review 8.  Mannose-binding lectin deficiency--revisited.

Authors:  Peter Garred; Flemming Larsen; Hans O Madsen; Claus Koch
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

Review 9.  Clinical potential of mannose-binding lectin-replacement therapy.

Authors:  J A Summerfield
Journal:  Biochem Soc Trans       Date:  2003-08       Impact factor: 5.407

10.  Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein.

Authors:  Flemming Larsen; Hans O Madsen; Robert B Sim; Claus Koch; Peter Garred
Journal:  J Biol Chem       Date:  2004-02-05       Impact factor: 5.157

View more
  52 in total

1.  CFTR mutation analysis and haplotype associations in CF patients.

Authors:  S K Cordovado; M Hendrix; C N Greene; S Mochal; M C Earley; P M Farrell; M Kharrazi; W H Hannon; P W Mueller
Journal:  Mol Genet Metab       Date:  2011-10-26       Impact factor: 4.797

2.  Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function.

Authors:  J Michael Collaco; Scott M Blackman; John McGready; Kathleen M Naughton; Garry R Cutting
Journal:  J Pediatr       Date:  2010-06-30       Impact factor: 4.406

Review 3.  Genetic variation and clinical heterogeneity in cystic fibrosis.

Authors:  Mitchell L Drumm; Assem G Ziady; Pamela B Davis
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

4.  TNF-alpha polymorphisms as a potential modifier gene in the cystic fibrosis.

Authors:  Cyntia Aac Coutinho; Fernando Al Marson; Aline Rb Marcelino; Luciana C Bonadia; Marcelo P Carlin; Antonio F Ribeiro; Jose D Ribeiro; Carmen S Bertuzzo
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

5.  The genetics and genomics of cystic fibrosis.

Authors:  N Sharma; G R Cutting
Journal:  J Cyst Fibros       Date:  2019-12-23       Impact factor: 5.482

6.  Phenotype-Specific Enrichment of Mendelian Disorder Genes near GWAS Regions across 62 Complex Traits.

Authors:  Malika Kumar Freund; Kathryn S Burch; Huwenbo Shi; Nicholas Mancuso; Gleb Kichaev; Kristina M Garske; David Z Pan; Zong Miao; Karen L Mohlke; Markku Laakso; Päivi Pajukanta; Bogdan Pasaniuc; Valerie A Arboleda
Journal:  Am J Hum Genet       Date:  2018-10-04       Impact factor: 11.025

7.  Missense variants in CFTR nucleotide-binding domains predict quantitative phenotypes associated with cystic fibrosis disease severity.

Authors:  David L Masica; Patrick R Sosnay; Karen S Raraigh; Garry R Cutting; Rachel Karchin
Journal:  Hum Mol Genet       Date:  2014-12-08       Impact factor: 6.150

Review 8.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

9.  Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.

Authors:  Claire L Keating; Xinhua Liu; Emily A Dimango
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

10.  Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice.

Authors:  Ahlke Heydemann; Ermelinda Ceco; Jackie E Lim; Michele Hadhazy; Pearl Ryder; Jennifer L Moran; David R Beier; Abraham A Palmer; Elizabeth M McNally
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.